Boehringer Ingelheim, a Germany-based biopharmaceutical company, announced on Friday that it has received a Commissioner's National Priority Voucher (CNPV) for HERNEXEOS (zongertinib tablets).

HERNEXEOS is currently under investigation for first-line use in treatment-naive patients with HER2 (ERBB2)-mutant advanced non-small cell lung cancer (NSCLC).

The CNPV program looks to reduce the review process from a typical tome-scale of 10-12 months to one to two months, while maintaining the FDA's rigorous safety and efficacy standards.

This honour is claimed to reflect the potential of HERNEXEOS to meet critical patient requirements for this rare and aggressive cancer.

The FDA chose HERNEXEOS for the CNPV program.